Ultragenyx terminates UX701 gene therapy for Wilson disease after trial fails to meet criteria

Ultragenyx Pharmaceutical announced its UX701 AAV9 gene therapy for Wilson disease failed to meet criteria and is being terminated.

Detected & updated continuously · Source: Nebula